24 X 7 online support

drp.ranjan78@gmail.com

Contact Us

+91-9815978530, +91-7999634444 ,
+91 - 7999632222

Make Appointment

iTind

iTind

ITind

The iTind (Temporarily Implanted Nitinol Device) treatment is a minimally invasive treatment which takes 5 to 7 days with immediate results. It is a clinically-proven treatment that relieves lower urinary tract symptoms due to an enlarged prostate, or BPH.

What is iTind?

iTind is a temporary nitinol device that gently reshapes the prostate to relieve BPH symptoms. The minimally invasive procedure requires no cutting or permanent implants, making it an ideal solution for men seeking effective treatment with minimal downtime.

Who is a Candidate for iTind?

The iTind procedure is a new alternative to prescription drugs or major surgery, and is ideal for sexually active men who want a minimally-invasive treatment that preserves a high quality of life. Men with moderate to severe BPH symptoms are generally good candidates for the procedure.

Benefits of iTind

The iTind procedure is a new alternative to prescription medication or invasive surgery.
Alternative to Daily Medication
It gives patients an option if they do not want to take a pill every day, or if they have tried standard drug treatments and were unsatisfied with the level of symptomatic relief.

How Does it Work?

The iTind treatment is a simple procedure performed by a urologist in our clinic.
The device is placed in the prostatic urethra in a folded configuration. During the 5 to 7-day treatment, it slowly expands and exerts gentle pressure at three precise points to widen the opening through which urine flows through the prostatic urethra and then out of the body. After 5 to 7 days, the device is completely removed. Clinical trials demonstrate that the newly remodeled prostatic urethra will continue to provide long-lasting relief of BPH symptoms.

Procedure

In your doctor’s office you may receive some light sedation and a local anesthetic.

A cystoscope is a miniature camera which will be inserted into your urethra to place the iTind device in your prostatic urethra. Once in place you should be able to urinate freely, so there is no need for a catheter and you will be released to go home. During the next 5 to 7 days you may resume most normal activities, depending on how comfortable you feel. The most common side effect reported while the iTind is in place is pressure around the area of the perineum and increased urgency and frequency to urinate. Some patients also experience some light blood in their urine and slight burning when urinating. After 5 to 7 days, your doctor will completely remove the iTind device using a flexible silicone catheter. Once this is done, you may return to your normal life.

Duration

The insertion of the iTind device into the prostatic urethra generally takes a few short hours. Following the initial insertion, it takes 5 to 7 days for the iTind device to widen the prostatic urethra, during which patients may resume their daily activities.

Recovery

After insertion of the iTind device, you may be kept for a few hours for observation. Upon returning home you may resume most normal activities depending on your personal level of comfort.

FAQ

Most patients start to experience symptom relief right after the removal. Symptoms typically continue to improve over the following 6 to 12 weeks.

The device positioning helps to ensure that no damage is caused to sperm ducts or sphincters, avoiding risks of sexual dysfunction. Sexual function was preserved among patients treated in the relevant clinical studies.

Durability has been demonstrated out to three years in terms of symptom improvement, urinary flow and quality of life in a significant number of patients. The iTind treatment does not preclude retreatment or other BPH treatments, should they be needed or desired in the future.

If you have had a previous surgical treatment on your prostate, or have a large median lobe, you may not be a candidate for the iTind procedure. Consult with your doctor to determine whether the iTind is right for you.

Clinical data demonstrates three years durability of the first generation TIND and efficacy at 24 months of the second-generation iTind. Both studies demonstrated preservation of sexual function and urinary continence and a very high safety profile. 

Medi-Tate develops and manufactures iTind for the treatment of BPH. The company is based in Israel. Medi-Tate Ltd. is now part of the Olympus Group.